January 14, 2026
Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease
Fortress Biotech has announced that its subsidiary, Cyprium Therapeutics, received US Food and Drug Administration (FDA) approval for Zycubo (copper histidinate, earlier known as CUTX-101) as a treatment for Menkes disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







